Mediar Therapeutics
Rahul Ballal is an experienced leader in the biotechnology and therapeutic sectors, currently serving as CEO of Mediar Therapeutics since February 2023 and as a board member for several companies including InduPro, Enliven Therapeutics, Agios Pharmaceuticals, and Vaderis Therapeutics AG. With a strong focus on innovative treatment approaches, particularly in the areas of fibrosis, oncology, and rare diseases, Rahul has previously held significant roles such as CEO of Imara, Inc. and Vice President of Business Development at Flexion Therapeutics. Rahul's educational background includes a Ph.D. in Biochemistry and Molecular Biology from Georgetown University School of Medicine, an MS in Bioinformatics from The Johns Hopkins University, and a BS in Biology from Brown University.
Mediar Therapeutics
Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.